MCID: CNT018
MIFTS: 36

Central Nervous System Leukemia

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Central Nervous System Leukemia

MalaCards integrated aliases for Central Nervous System Leukemia:

Name: Central Nervous System Leukemia 12 15 70
Leukemia of the Cns 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12969
NCIt 50 C5440
UMLS 70 C1332884

Summaries for Central Nervous System Leukemia

Disease Ontology : 12 A hematologic cancer located in the central nervous system.

MalaCards based summary : Central Nervous System Leukemia, also known as leukemia of the cns, is related to severe combined immunodeficiency and acute leukemia. An important gene associated with Central Nervous System Leukemia is CD19 (CD19 Molecule), and among its related pathways/superpathways are Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Etoposide and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include central nervous system, myeloid and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Central Nervous System Leukemia

Diseases related to Central Nervous System Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)
# Related Disease Score Top Affiliating Genes
1 severe combined immunodeficiency 29.8 CD7 CD34 CD19
2 acute leukemia 29.6 KMT2A CD7 CD34 CD33 ANPEP AFF1
3 t-cell acute lymphoblastic leukemia 29.4 CD34 CD33 ABL1
4 lymphoma, non-hodgkin, familial 29.4 MME KMT2A CD7 CD34 CD19
5 leukemia, chronic myeloid 29.4 KMT2A CD34 CD33 ABL1
6 childhood acute lymphocytic leukemia 29.0 MME KMT2A CD34 ANPEP ABL1
7 b-lymphoblastic leukemia/lymphoma 29.0 MME KMT2A CD34 CD19 ANPEP ABL1
8 acute promyelocytic leukemia 29.0 KMT2A CD7 CD34 CD33 ANPEP
9 precursor t-cell acute lymphoblastic leukemia 28.8 KMT2A CD7 CD34 CD33 ANPEP ABL1
10 pancytopenia 28.8 KMT2A CD7 CD34 CD33 CD19 ANPEP
11 leukemia, acute lymphoblastic 28.7 MME KMT2A CD7 CD34 CD33 CD19
12 leukemia, acute myeloid 28.1 MME KMT2A CD7 CD34 CD33 CD19
13 leukemia 10.7
14 cerebral lymphoma 10.3 MME CD19
15 myeloid leukemia 10.3
16 adult lymphoma 10.3 MME CD19
17 spleen cancer 10.2 MME CD19
18 mulchandani-bhoj-conlin syndrome 10.2 MME CD19
19 cll/sll 10.2 MME CD19
20 childhood leukemia 10.2
21 central nervous system hematologic cancer 10.2 MME CD19
22 lymphoplasmacytic lymphoma 10.2 MME CD19
23 gallbladder lymphoma 10.2 MME CD33
24 plasma protein metabolism disease 10.2 MME CD19
25 aleukemic leukemia cutis 10.2 CD33 ANPEP
26 intravascular large b-cell lymphoma 10.2 MME KMT2A
27 burkitt lymphoma 10.1
28 lymphoma, hodgkin, classic 10.1
29 papilledema 10.1
30 paraplegia 10.1
31 monocytic leukemia 10.1
32 diabetes insipidus 10.1
33 hypereosinophilic syndrome 10.1
34 tibial nerve palsy 10.1 CD34 CD19
35 breast leiomyoma 10.1 MME CD34
36 cardiomyopathy, dilated, 1c, with or without left ventricular noncompaction 10.1 CD33 CD19
37 breast myofibroblastoma 10.1 MME CD34
38 pacinian tumor 10.1 MME CD34
39 mucocele of appendix 10.1 MME CD34
40 breast rhabdomyosarcoma 10.1 CD33 ANPEP
41 inflammatory liposarcoma 10.1 MME CD34
42 cervical polyp 10.1 MME CD34
43 intravenous leiomyomatosis 10.1 MME CD34
44 sarcomatoid squamous cell skin carcinoma 10.1 MME CD34
45 pulmonary artery leiomyosarcoma 10.1 MME CD34
46 vaginal endometrial stromal sarcoma 10.1 MME CD34
47 vulvar leiomyoma 10.1 MME CD34
48 sclerosing hepatic carcinoma 10.1 MME CD34
49 breast sarcoma 10.1 MME CD34
50 breast malignant phyllodes tumor 10.1 MME CD34

Graphical network of the top 20 diseases related to Central Nervous System Leukemia:



Diseases related to Central Nervous System Leukemia

Symptoms & Phenotypes for Central Nervous System Leukemia

GenomeRNAi Phenotypes related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

26 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.68 WFIKKN2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-131 9.68 WFIKKN2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.68 AFF1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.68 WFIKKN2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.68 CD34
6 Increased shRNA abundance (Z-score > 2) GR00366-A-150 9.68 WFIKKN2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.68 AFF1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.68 WFIKKN2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.68 WFIKKN2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.68 WFIKKN2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-203 9.68 AFF1 CD34
12 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.68 CD34
13 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.68 WFIKKN2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.68 AFF1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.68 CD34
16 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.68 AFF1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-58 9.68 AFF1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-59 9.68 AFF1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.68 AFF1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.68 WFIKKN2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.68 AFF1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-84 9.68 WFIKKN2

MGI Mouse Phenotypes related to Central Nervous System Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.23 ABL1 AFF1 ANPEP CD19 CD34 CD7

Drugs & Therapeutics for Central Nervous System Leukemia

Drugs for Central Nervous System Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
2
Cytarabine Approved, Investigational Phase 2, Phase 3 147-94-4 6253
3
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
6
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
7
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
8
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
9
Pegaspargase Approved, Investigational Phase 2, Phase 3 130167-69-0
10
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
11
Mercaptopurine Approved Phase 2, Phase 3 50-44-2 667490
12
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
13
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
15 Gastrointestinal Agents Phase 2, Phase 3
16 Vitamin B9 Phase 2, Phase 3
17 Folic Acid Antagonists Phase 2, Phase 3
18 Tubulin Modulators Phase 2, Phase 3
19 Antibiotics, Antitubercular Phase 2, Phase 3
20 Antirheumatic Agents Phase 2, Phase 3
21 Etoposide phosphate Phase 2, Phase 3
22 Hormone Antagonists Phase 2, Phase 3
23 Antimitotic Agents Phase 2, Phase 3
24 glucocorticoids Phase 2, Phase 3
25 Antiemetics Phase 2, Phase 3
26 Immunosuppressive Agents Phase 2, Phase 3
27
Liposomal doxorubicin Phase 2, Phase 3 31703
28 Immunologic Factors Phase 2, Phase 3
29 Hormones Phase 2, Phase 3
30 Antineoplastic Agents, Hormonal Phase 2, Phase 3
31 Alkylating Agents Phase 2, Phase 3
32 Vitamin B Complex Phase 2, Phase 3
33 Histone Deacetylase Inhibitors Phase 2, Phase 3
34 Antiviral Agents Phase 2, Phase 3
35 Dermatologic Agents Phase 2, Phase 3
36 Folate Phase 2, Phase 3
37 Antimetabolites Phase 2, Phase 3
38 Anti-Bacterial Agents Phase 2, Phase 3
39 Anti-Inflammatory Agents Phase 2, Phase 3
40 Anti-Infective Agents Phase 2, Phase 3
41 Cola

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma Unknown status NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
2 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
3 Descriptive Study to Evaluate the Information and Psychosocial Issues on the Risk on Infertility in Cancer Patients After Receiving Treatment in a Comprehensive Cancer Center Unknown status NCT01295463

Search NIH Clinical Center for Central Nervous System Leukemia

Genetic Tests for Central Nervous System Leukemia

Anatomical Context for Central Nervous System Leukemia

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Leukemia:

19
Central Nervous System

MalaCards organs/tissues related to Central Nervous System Leukemia:

40
Myeloid, Bone, Bone Marrow, Brain, Eye, Thyroid

Publications for Central Nervous System Leukemia

Articles related to Central Nervous System Leukemia:

(show top 50) (show all 262)
# Title Authors PMID Year
1
Comparison of outcomes of children with acute lymphoblastic leukemia treated with BMF protocol across 2 decades. 61
33170046 2021
2
The diagnostic and prognostic value of MRI in central nervous system involvement of acute myeloid leukemia: a retrospective cohort of 84 patients. 61
32567523 2020
3
Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children With Central Nervous System Leukemia. 61
33526401 2020
4
Prognostic factors for clinical outcomes of patients with central nervous system leukemia. 61
33271117 2020
5
Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation. 61
32332920 2020
6
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. 61
32845001 2020
7
Imaging features, clinicopathological analysis and diagnostic strategy of IgG4-related hypertrophic pachymeningitis. 61
32819129 2020
8
Revealing the molecular mechanism of central nervous system leukemia with single-cell technology. 61
32650214 2020
9
Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT. 61
31785158 2020
10
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. 61
32453841 2020
11
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. 61
31944221 2020
12
[Clinical Analysis of Dasatinib and Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia]. 61
32027247 2020
13
Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM. 61
30655370 2019
14
Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL. 61
30846865 2019
15
[The efficacy analysis of allogeneic hematopoietic stem cell transplantation in 48 leukemia patients with central nervous system leukemia]. 61
32397021 2019
16
Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor. 61
30518632 2019
17
[Detection Rate of Central Nervous System Leukemia Can Be Improved by Cell Preservation Solution]. 61
30738441 2019
18
A Case of Acute Lymphocytic Leukaemia with t(3;13) and Central Nervous System Leukemia after Allogenic Cord Blood Transplantation. 61
32634197 2019
19
Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling. 61
30444200 2019
20
Altered CSF Proteomic Profiling of Paediatric Acute Lymphocytic Leukemia Patients with CNS Infiltration. 61
31186631 2019
21
[Clinical Significance of Additional Chromosomal 8 Clonal Evolution in CML Progression]. 61
30501690 2018
22
Rhabdomyolysis during myelosuppression in a patient with central nervous system leukemia: A case report. 61
30407314 2018
23
Chronic myeloid leukemia extramedullary blast crisis presenting as central nervous system leukemia: A case report. 61
30407337 2018
24
Identifying and Understanding the Gaps in Care Experienced by Adolescent and Young Adult Cancer Patients at the University of Iowa Hospitals and Clinics. 61
29924681 2018
25
Radiation in Central Nervous System Leukemia: Guidelines From the International Lymphoma Radiation Oncology Group. 61
30102203 2018
26
[Analysis of Factors Influencing Prognosis of 87 Adults with Ph Chromosome Negative ALL]. 61
30111399 2018
27
[Treatment of central nervous system leukemia with CD19-chimeric antigen receptor T-cell immunotherapy: two cases report and literature review]. 61
30180466 2018
28
[Analysis of Prognostic Factors for 96 Patients with Acute Lymphoblastic Leukemia]. 61
30111398 2018
29
Haploidentical hematopoietic SCT using helical tomotherapy for total-body irradiation and targeted dose boost in patients with high-risk/refractory acute lymphoblastic leukemia. 61
29330392 2018
30
A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia. 61
29387211 2018
31
Experiment research of focused ultrasound combined with drug and microbubble for treatment of central nervous system leukemia. 61
29435190 2018
32
Central nervous system leukemia in a patient with concurrent nasopharyngeal carcinoma and acute myeloid leukaemia: A case report. 61
29384905 2017
33
[Clinical Analysis of 7 Children with Mature B-cell Acute Lymphoblastic Leukemia]. 61
29070107 2017
34
Outcome and Clinical Significance of Immunophenotypic Markers Expressed in Different Treatment Protocols of Pediatric Patients With T-ALL in Developing Countries. 61
28624542 2017
35
Severe Hyponatremia in a Single-Center Series of 84 Homogenously Treated Children With Acute Lymphoblastic Leukemia. 61
28060134 2017
36
The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system. 61
27686375 2017
37
[Clinical Characteristics and Prognosis of 21 Cases of Acute Lymphoblastic Leukemia with Central Nervous System Leukemia]. 61
28024476 2016
38
[Critical roles of matrix metalloproteinases secreted by leukemic cells in the pathogenesis of central nervous system leukemia]. 61
28088972 2016
39
[The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia]. 61
27431075 2016
40
Transverse myelopathy occurring with intrathecal administration of methotrexate and cytarabine chemotherapy: A case report. 61
27313742 2016
41
Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies. 61
26485054 2016
42
Paving the road ahead for CD19 CAR T-cell therapy. 61
26335422 2015
43
[Leukotriene B4 level in cerebrospinal fluid of patients with tuberculosis meningitis and clinical significance]. 61
26271986 2015
44
Blastic plasmacytoid dendritic cell neoplasm with leukemic manifestation and ETV6 gene rearrangement: A case report. 61
25780395 2015
45
Comprehensive craniospinal radiation for controlling central nervous system leukemia. 61
25539370 2014
46
Advances in treatment of de-novo pediatric acute myeloid leukemia. 61
25226383 2014
47
Superior survival of unmanipulated haploidentical hematopoietic stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with standard-risk acute lymphoblastic leukemia in first complete remission. 61
24747334 2014
48
Establishment of NOD/SCID mouse model of central nervous system leukemia. 61
24927394 2014
49
[Research progress on drug-loaded microbubble targeting treatment of central nervous system leukemia]. 61
24989314 2014
50
The emerging and diverse roles of sirtuins in cancer: a clinical perspective. 61
24133372 2013

Variations for Central Nervous System Leukemia

Expression for Central Nervous System Leukemia

Search GEO for disease gene expression data for Central Nervous System Leukemia.

Pathways for Central Nervous System Leukemia

Pathways related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.56 CD34 CD33 CD19
2 11.42 MME CD34 CD33 CD19 ANPEP
3 11.2 MME CD34 CD19
4 11.1 MME CD7 CD34 CD33 CD19 ANPEP

GO Terms for Central Nervous System Leukemia

Cellular components related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.26 MME HRG CD34 CD33
2 external side of plasma membrane GO:0009897 8.92 CD34 CD33 CD19 ANPEP

Biological processes related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.43 CD34 CD33 CD19
2 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 9.16 CD19 ABL1
3 positive regulation of focal adhesion assembly GO:0051894 8.96 HRG ABL1
4 B cell proliferation involved in immune response GO:0002322 8.62 CD19 ABL1

Molecular functions related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 8.8 CD7 CD33 ANPEP

Sources for Central Nervous System Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....